Imperiale T F, McCullough A J
Case Western Reserve University School of Medicine, Cleveland, Ohio.
Ann Intern Med. 1990 Aug 15;113(4):299-307. doi: 10.7326/0003-4819-113-4-299.
To determine whether corticosteroids affect short-term mortality from alcoholic hepatitis.
Studies published from 1966 to 1989 were identified through a MEDLINE computer search and an extensive manual search of the bibliographies of identified articles.
We found 11 randomized studies (10 of which were placebo controlled) that assessed mortality in hospitalized patients diagnosed with acute alcoholic hepatitis and treated with corticosteroids.
Two critical appraisers independently evaluated trial quality and abstracted quantitative data on clinical characteristics of the populations, interventions, and all-cause mortality.
Overall, the protective efficacy (or percent reduction in mortality) of corticosteroids was 37% (95% CI, 20% to 50%). Protective efficacy was higher among trials with higher quality scores and trials that excluded subjects with active gastrointestinal bleeding. In subjects with hepatic encephalopathy, protective efficacy was 34% overall (CI, 15% to 48%). It was also higher among trials with higher quality scores and trials excluding subjects with acute gastrointestinal bleeding, but was not present among trials with lower quality scores or trials that did not exclude subjects with acute gastrointestinal bleeding. In subjects without hepatic encephalopathy, corticosteroids had no protective effect, and this lack of efficacy was consistent across all trial subgroups.
These results suggest that corticosteroids reduce short-term mortality in patients with acute alcoholic hepatitis who have hepatic encephalopathy, that the protective effect depends on the exclusion criterion of acute gastrointestinal bleeding and is influenced by trial quality, and that corticosteroids are of no benefit in patients without hepatic encephalopathy.
确定皮质类固醇激素是否会影响酒精性肝炎的短期死亡率。
通过医学文献数据库(MEDLINE)计算机检索以及对已识别文章的参考文献进行广泛的人工检索,找出1966年至1989年发表的研究。
我们发现了11项随机研究(其中10项为安慰剂对照研究),这些研究评估了被诊断为急性酒精性肝炎并接受皮质类固醇激素治疗的住院患者的死亡率。
两名关键评估者独立评估试验质量,并提取有关研究人群的临床特征、干预措施和全因死亡率的定量数据。
总体而言,皮质类固醇激素的保护效果(或死亡率降低百分比)为37%(95%置信区间,20%至50%)。在质量评分较高的试验以及排除有活动性胃肠道出血受试者的试验中,保护效果更高。在患有肝性脑病的受试者中,总体保护效果为34%(置信区间,15%至48%)。在质量评分较高的试验以及排除急性胃肠道出血受试者的试验中,保护效果也更高,但在质量评分较低的试验或未排除急性胃肠道出血受试者的试验中则不存在这种效果。在没有肝性脑病的受试者中,皮质类固醇激素没有保护作用,并且在所有试验亚组中这种无效性都是一致的。
这些结果表明,皮质类固醇激素可降低患有肝性脑病的急性酒精性肝炎患者的短期死亡率,保护作用取决于急性胃肠道出血的排除标准,并受试验质量影响,且皮质类固醇激素对没有肝性脑病的患者没有益处。